10.52 USD
↘ 0.33 (3.04%)AT CLOSE (11:59 AM EDT)
Daxor Corporation Common Stock
DXRNASDAQ • USD
10.35
↘ 0.17 (1.65%)
POST MARKET (AS OF 04:11 PM EDT)
Post Market
AS OF 04:11 PM EDT
10.35
↘ 0.17 (1.65%)
Market: CLOSED
Daxor Corporation Common Stock (DXR) trades at $10.51 per share. Technicals currently rate "Neutral" while our fundamental analysis reads "Sell". Key drivers include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity and a bearish Death Cross on the long-term moving averages. DXR is fairly valued relative to its sector peers based on current multiples.
Technical & fundamental data as of Aug 4, 2026.
Open?$10.11
High?$11.00
Low?$10.11
Prev. Close?$10.85
Volume?3.1K
Avg. Volume?2.2K
VWAP?$10.90
Rel. Volume?1.39x
Bid / Ask
Bid?$7.31 × 100
Ask?$14.04 × 100
Spread?$6.73
Midpoint?$10.67
Valuation & Ratios
Market Cap?63.3M
Shares Out?5.8M
Float?2.0M
Float %?40.5%
P/E Ratio?N/A
P/B Ratio?1.75
EPS?-$0.62
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA offers unmatched, real-time, precise data via its rapid, hand-held, lab-based system.
Employees
750
Market Cap
63.3M
Industry
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Website
Listed
1983-07-25
Address
350 FIFTH AVENUE
NEW YORK, NY 10118
Phone: (212) 244-0555
NEW YORK, NY 10118
Phone: (212) 244-0555
Technical OutlookNeutral
Strong SellNeutralStrong Buy
Long-Term (Tide)?– Neutral(0/3)
Medium-Term (Wave)?– Neutral(0/3)
Short-Term (Ripple)?▼ Bearish(-2/3)
MA Alignment?Mixed
Full Technical Analysis →Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?3
Z-Score?19
Momentum?17
Short Sent.?80
Piotroski F-Score?0/9Weak
Altman Z-Score?1.44Distress
Confidence?31%Very Low
Short InterestLow
Short % of Float?0.07%Low
Short Interest?1.5K
Days to Cover?1.0
Free Float2.0M
Avg Daily Volume1.4K
Settlement Date2026-07-15
Financial Health
Current Ratio?1.66Adequate
Quick Ratio?1.65Adequate
Cash Ratio?0.00Low
Debt/Equity?1.03Moderate
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score67/100
P/E?N/A▾
P/B?1.75CHEAP▾
Peers100
S&P81
P/S?44.29HIGH▾
Peers100
S&P3
P/FCF?N/A▾
EV/EBITDA?-20.4CHEAP▾
S&P97
EV/Sales?70.25HIGH▾
Peers100
S&P3
Returns & Efficiency
ROE?-9.9%WEAK▾
S&P9
ROA?-4.2%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?N/A
Enterprise Value?$100.5M
Fundamentals ratios updated end of day